UNSPSC 51263010: Terazosin hydrochloride

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H25N5O4.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D32S14F082, chemically known as 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine but more generally known as terazosin hydrochloride, which bears US NIH Compound Identifier 5401. European Medicines Agency schedules Terazosin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04722MIG.

UNSPSC 51263010 Terazosin hydrochloride, a Commodity code, shows a significant mismatch between its nominal scope—a specific pharmaceutical product—and the recent state and local solicitations tagged under it. The two recent opportunities on record involve naloxone and safe drug deactivation systems (Seminole County, Florida) and a therapeutic pharmacy initiative request for information from the Texas Health and Human Services Commission; neither directly addresses terazosin hydrochloride procurement. The code appears to capture pharmaceutical products and related pharmacy benefit administration, but the tagged opportunities reflect opioid-reversal agents and direct-to-manufacturer prescription programs rather than the antihypertensive medication the code nominally describes. State and local issuing bodies using this code include county health agencies and state health and human services commissions, though the sparse recent record limits characterization of issuing-body concentration or repeat buyers.

Geographic activity is limited to Florida and Texas based on the two most recent opportunities. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, using a competitive bidding process with a July 26, 2023 response deadline. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, requesting vendor information on direct-to-manufacturer prescription fulfillment capabilities and market approaches for a therapeutic pharmacy initiative, with the same April 3, 2026 response deadline. The code shows limited recent activity overall; practitioners should verify whether opportunities posting under this code align with their product or service offering before pursuing.